Metabolism of a Novel Anxiolytic GML-1 in Rats

A. A. Novitskii; P. O. Bochkov; R. V. Shevchenko; O. G. Gribakina; A. A. Litvin; G. B. Kolyvanov; V. P. Zherdev

doi:10.1007/s10517-018-4257-9

Metabolism of a Novel Anxiolytic GML-1 in Rats

Authors: Novitskii A.A.¹, Bochkov P.O.¹, Shevchenko R.V.¹, Gribakina O.G.¹, Litvin A.A.¹, Kolyvanov G.B.¹, Zherdev V.P.¹
Affiliations:
1. Laboratory of Pharmacokinetics, V. V. Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences
Issue: Vol 165, No 6 (2018)
Pages: 751-753
Section: Pharmacology and Toxicology
URL: https://journals.rcsi.science/0007-4888/article/view/240721
DOI: https://doi.org/10.1007/s10517-018-4257-9
ID: 240721

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Statistics

Abstract

Metabolism of a novel anxiolytic GML-1 (N-benzyl-N-methyl-1-phenylpyrrolo[1,2-a]pirazin-3-carboxamide) in rat blood plasma was studied by HPLC-mass spectrometry. Three biotransformation products with the corresponding molecular ions were detected. A conclusion was made that the main pathways of GML-1 metabolism are oxidative reactions yielding hydroxylated, methylated, and demethylated metabolites.